NGM282

Aldafermin · NGM Biopharmaceuticals

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for NGM282, covering 2015-11-17 to 2025-06-26. Get the full timeline:

Most recent: Clinical Trial Update: Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) [Phase 2]